NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis $1.59 +0.08 (+5.30%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.40▼$1.6350-Day Range$1.07▼$1.6352-Week Range$1.05▼$3.77Volume1.01 million shsAverage Volume1.45 million shsMarket Capitalization$130.65 millionP/E RatioN/ADividend YieldN/APrice Target$14.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Adicet Bio alerts: Email Address Adicet Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside793.1% Upside$14.20 Price TargetShort InterestHealthy6.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingSelling Shares$8,437 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.37) to ($1.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.36 out of 5 starsMedical Sector334th out of 936 stocksPharmaceutical Preparations Industry155th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdicet Bio has only been the subject of 2 research reports in the past 90 days.Read more about Adicet Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.50% of the outstanding shares of Adicet Bio have been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Adicet Bio has recently decreased by 16.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 3.7 News and Social Media Coverage News SentimentAdicet Bio has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adicet Bio this week, compared to 1 article on an average week.Search Interest8 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows5 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,437.00 in company stock.Percentage Held by Insiders19.10% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adicet Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to decrease in the coming year, from ($1.37) to ($1.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adicet Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Adicet Bio Stock (NASDAQ:ACET)Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Read More ACET Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACET Stock News HeadlinesJuly 25 at 11:37 AM | msn.comWhy Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds?July 23 at 6:11 AM | sg.finance.yahoo.com0HX7.IL,0P0001KQGG,3177 (0HX7.IL)July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 22, 2024 | finance.yahoo.comOwning 44% shares,institutional owners seem interested in Adicet Bio, Inc. (NASDAQ:ACET),July 16, 2024 | americanbankingnews.comShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Declines By 9.4%July 2, 2024 | investorplace.com3 Clinical-Stage Biotech Stocks to Buy for Multibagger ReturnsJune 24, 2024 | businesswire.comAdicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaJune 10, 2024 | investorplace.comUnder-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 5, 2024 | businesswire.comAdicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus NephritisMay 31, 2024 | businesswire.comAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare ConferenceMay 21, 2024 | markets.businessinsider.comJMP Securities Sticks to Their Hold Rating for Adicet Bio (ACET)May 14, 2024 | msn.comACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024May 14, 2024 | markets.businessinsider.comAdicet Bio, Inc Q1 Loss DeclinesMay 14, 2024 | businesswire.comAdicet Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 14, 2024 | businesswire.comAdicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid CongressMay 7, 2024 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences ConferenceSee More Headlines Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$14.20 High Stock Price Target$27.00 Low Stock Price Target$5.00 Potential Upside/Downside+793.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.79% Return on Assets-47.60% Debt Debt-to-Equity RatioN/A Current Ratio14.34 Quick Ratio14.34 Sales & Book Value Annual Sales$24.99 million Price / Sales5.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.43 per share Price / Book0.65Miscellaneous Outstanding Shares82,170,000Free Float66,479,000Market Cap$130.65 million OptionableOptionable Beta1.80 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Chen Schor BA (Age 52)CPA, M.B.A., CEO, President & Director Comp: $871.97kDr. Aya Jakobovits Ph.D. (Age 69)Founder & Independent Director Comp: $45kMr. Brian Nicholas Harvey (Age 63)Chief Financial Officer Comp: $594.94kDr. Donald Healey Ph.D. (Age 62)Chief Technology Officer Comp: $606.34kDr. Blake Aftab Ph.D. (Age 43)Senior VP & Chief Scientific Officer Comp: $675.04kMs. Amy LockeChief Human Resource OfficerDr. Francesco Galimi M.D. (Age 56)Ph.D., Chief Medical Officer & Senior VP Comp: $680.37kDr. Nancy L. Boman M.D.Ph.D., Senior VP & Chief Regulatory OfficerMore ExecutivesKey CompetitorsTitan MachineryNASDAQ:TITNUnited RentalsNYSE:URIW.W. GraingerNYSE:GWWFastenalNASDAQ:FASTWatscoNYSE:WSOView All CompetitorsInsiders & InstitutionsMichael KauffmanSold 5,900 sharesTotal: $8,437.00 ($1.43/share)RA Capital Management L.P.Bought 7,541,000 shares on 5/17/2024Ownership: 9.177%Blackstone Inc.Bought 1,236,453 shares on 5/16/2024Ownership: 1.505%Bayesian Capital Management LPBought 38,421 shares on 5/16/2024Ownership: 0.047%Price T Rowe Associates Inc. MDBought 15,344 shares on 5/15/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions ACET Stock Analysis - Frequently Asked Questions How have ACET shares performed this year? Adicet Bio's stock was trading at $1.89 at the beginning of 2024. Since then, ACET stock has decreased by 15.9% and is now trading at $1.59. View the best growth stocks for 2024 here. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) posted its earnings results on Tuesday, May, 14th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). Who are Adicet Bio's major shareholders? Top institutional shareholders of Adicet Bio include Concourse Financial Group Securities Inc.. Insiders that own company stock include Orbimed Advisors Llc, Don Healey, Francesco Galimi, Chen Schor, Blake Aftab, Steve Dubin, Andrew Sinclair and Aya Jakobovits. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR) and General Electric (GE). This page (NASDAQ:ACET) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
